ABCL News and Press, AbCellera Biologics Inc. From 09/13/23

2023-09-13 10:25:54 ET More on AbCellera, Incyte, etc. AbCellera Biologics Inc. ( ABCL ) Q2 2023 Earnings Call Transcript AbCellera Biologics Inc. 2023 Q2 - Results - Earnings Call Presentation Incyte Corporation ( INCY ) Q2 2023 Earnings Call Transcript ...

AbCellera (Nasdaq:ABCL) announced today that it has entered into a strategic collaboration with Incyte (Nasdaq:INCY) to discover and develop therapeutic antibodies in oncology. “We are excited to partner with Incyte, which has a track record of developing first-in-class medicines and...

2023-09-04 12:00:00 ET More on AI Cathie Wood's 'Big Ideas 2023' sees Artificial Intelligence as the future Artificial intelligence is a '1995 moment' for tech. That could push stocks even higher Apple CEO Tim Cook says artificial intelligence 'is a major focus of ou...

2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...

2023-08-04 16:49:52 ET Summary Time in the market and compounding interest are crucial for building wealth over time. Even average investors can build generational wealth through discipline and time in the market. I plan to open a Roth IRA for my newborn son and present a list...

2023-08-04 01:00:28 ET Image source: The Motley Fool. AbCellera Biologics (NASDAQ: ABCL) Q2 2023 Earnings Call Aug 03, 2023 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics (ABCL) Q2 2023 Earnings Call...

2023-08-03 16:47:21 ET AbCellera Biologics press release ( NASDAQ: ABCL ): Q2 GAAP EPS of -$0.11 beats by $0.01 . Revenue of $10M (-78.1% Y/Y) misses by $2.21M . For further details see: AbCellera Biologics GAAP EPS of -$0.11 beats by $0.01, revenue of $1...

Total revenue of $10 million, compared to $46 million in Q2 2022 Total cumulative partnered program starts of 106, up 20% from Q2 2022 Net loss of $0.11 per share on a basic and diluted basis, compared to a net loss of $0.02 per share on a basic and diluted basis in Q2 2022 ...

PTAB rejects request by Berkeley Lights to reconsider its decision denying Berkeley's argument that AbCellera’s U.S. patent is invalid AbCellera (Nasdaq: ABCL) announced that the United States Patent and Trademark Office’s (USPTO) Patent Trial and Appeal Board (PTAB) h...

2023-07-19 01:26:24 ET Summary AbCellera Biologics, a multinational company focused on antibody drug development, experienced a drop in revenue due to reduced demand for its COVID-19 antibody treatments. Despite financial setbacks, ABCL remains operational and continues to form pa...